



## **Ion Channel Drug Discovery - Beyond the Bottlenecks and Ready for CiPA**

Andrea Brüggemann, Nanion Technologies

Niels Fertig, Nanion Technologies

Markus Rapedius, Nanion Technologies

Monday, February 13<sup>th</sup>, 2017, 12:30 – 2:00 PM

Nanion Technologies is one of the leading providers of automated patch clamp systems, offering a diverse product portfolio for experiments ranging from single channel recordings to HTS-compatible ion channel drug discovery. During this workshop, we will demonstrate how to push the boundaries of patch clamp-based ion channel high throughput screening projects of various voltage- and ligand gated targets, and how to get ready for CiPA-compliant safety screening beyond hERG.

The CiPA initiative is an ongoing validation program aimed at improving the regulatory requirements for proarrhythmia risk assessment. In accordance with the CiPA-initiative, the panel of cardiac ion channels to consider will drastically expand, consequently requiring increased data throughput for early compound safety prediction.

The *SyncroPatch 384/768PE*, an automated patch clamp platform recording from up to 768 cells simultaneously, allows the highest data throughput on the market supporting HTS of ion channel active compounds and early safety assessment on cardiac channels. Data of six different cardiac channels recorded in the voltage clamp mode, using one single plate, will be shown. The *SyncroPatch 384/768PE* also supports automated current clamp recordings, experiments at physiological temperature, and minimal cell usage, making it the ideal partner for safety testing on stem cell-derived cardiomyocytes.

The *CardioExcyte 96* is a hybrid system combining impedance and EFP recordings from beating cardiomyocyte networks from 96 wells in parallel. The *CardioExcyte 96* has proven a versatile tool for safety and toxicity screening applications serving as a powerful tool complementing APC.

Join our workshop to learn more about new safety screening strategies and how to keep up with the increasing demands on cardiac safety and toxicity screening.

Space is limited so reserve yours by sending an email to [info@nanion.de](mailto:info@nanion.de).